Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 3/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | MC5R | P33032 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9129308 | 0.94 | SIGMAR1 (0.58) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL6897512 | 0.94 | SIGMAR1 (0.53) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL7621730 | 0.92 | SIGMAR1 (0.56) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL8422096 | 0.92 | SIGMAR1 (0.56) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL9588844 | 0.92 | SIGMAR1 (0.56) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL31036062 | 0.92 | SIGMAR1 (0.56) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL9672316 | 0.91 | SIGMAR1 (0.47) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL314040 | 0.87 | CYP1A2 (0.56) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL30985268 | 0.87 | CYP1A2 (0.56) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL30746339 | 0.87 | SIGMAR1 (0.68) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059818-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200291015-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | disclosed |
| WO-2017160632-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-21 | — | — | WO | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| CN-101730677-B | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORP | 2014-07-16 | — | — | CN | disclosed |
| WO-2012062996-A1 | DERIVATIVES OF 6-AMINO-6-DEOXYGLUCOSAMINE AND USE OF SAME AS ANTIBACTERIAL AGENTS | UNIVERSITE JOSEPH FOURIER (FR) | 2012-05-18 | — | — | WO | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| EP-1578777-A2 | IAP BINDING COMPOUNDS | The Trustees of Princeton University (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004007529-A2 | IAP BINDING COMPOUNDS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-0512352-B1 | Substituted carboxylic acid derivatives | HOFFMANN LA ROCHE (CH) | 1996-03-27 | — | — | EP | disclosed |
| US-5422038-A | Ferroelectric liquid crystal material with sufficient spontaneous polarization, high speed response capability, wide temperature range | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-06-06 | — | — | US | disclosed |
| EP-0416946-B1 | Optically active naphthalene derivative, process for preparation thereof, liquid crystal composition containing the same as effective component, and liquid crystal element using the same | SUMITOMO CHEMICAL CO (JP) | 1994-11-09 | — | — | EP | disclosed |
| US-5344843-A | Carnitine acryltransferase enzyme inhibitors as antiischemic agents and for cardiovascular disorders | HOFFMAN-LA ROCHE INC. (US) | 1994-09-06 | — | — | US | disclosed |
| EP-0512352-A2 | Substituted carboxylic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-11-11 | — | — | EP | disclosed |
| EP-0416946-A2 | Optically active naphthalene derivative, process for preparation thereof, liquid crystal composition containing the same as effective component, and liquid crystal element using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-03-13 | — | — | EP | disclosed |
| EP-0250530-A1 | NEW ARYL DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-01-07 | — | — | EP | disclosed |
| WO-1987004152-A1 | NEW ARYL DERIVATIVES | THE WELLCOME FOUNDATION LTD. (GB) | 1987-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291015-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | MPO, NOX5, SERPINB1 | SIGMAR1 2852/4885CYP1A2 180/4885CYP2A6 1322/4885 |
| US-11059818-B2 | Triazolopyridine inhibitors of myeloperoxidase | MPO, NOX5, SERPINB1 | SIGMAR1 2852/4885CYP1A2 180/4885CYP2A6 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.